Patients enrolled (n=73)

Enrollment/eligibility criteria not met (n=1)
Consent withdrawn (n=1)

Randomized (n=71)

COHORT 1
Randomized (n=8)
Treated (n=8)

Discontinued*
- TEAE (n=0)
- Other (n=0)

Completed treatment (n=8)

Discontinued*
- Consent withdrawn (n=1)
- Loss to follow-up (n=0)
- Other (n=0)

Completed study (n=7)

COHORT 2
Randomized (n=9)
Treated (n=9)

Discontinued*
- TEAE (n=1)
- Other (n=1)

Completed treatment (n=9)

Discontinued*
- Consent withdrawn (n=0)
- Loss to follow-up (n=0)
- Other (n=0)

Completed study (n=8)

COHORT 3
Randomized (n=12)
Treated (n=12)

Discontinued*
- TEAE (n=2)
- Other (n=1)

Completed treatment (n=12)

Discontinued*
- Consent withdrawn (n=0)
- Loss to follow-up (n=0)
- Other (n=1)

Completed study (n=9)

COHORT 4
Randomized (n=11)
Treated (n=10)

Discontinued*
- TEAE (n=0)
- Other (n=0)

Completed treatment (n=11)

Discontinued*
- Consent withdrawn (n=0)
- Loss to follow-up (n=0)
- Other (n=0)

Completed study (n=8)

COHORT 5
Randomized (n=8)
Treated (n=8)

Discontinued*
- TEAE (n=0)
- Other (n=0)

Completed treatment (n=8)

Discontinued*
- Consent withdrawn (n=0)
- Loss to follow-up (n=1)
- Other (n=0)

Completed study (n=8)

PLACEBO
Randomized (n=23)
Treated (n=23)

Discontinued*
- TEAE (n=1)
- Other (n=1)

Completed treatment (n=23)

Discontinued*
- Consent withdrawn (n=0)
- Loss to follow-up (n=0)
- Other (n=0)

Completed study (n=20)

*NOTE: Excluding death; 2, 4, 5, 1, 1 and 6 patients in AZD9773 cohorts 1–5 and placebo cohort died, but these were considered to have completed treatment.